News Articles Tagged: Cardiorenal Disease

Advancing Cardiorenal Health: The Role of Finerenone

Discover how Finerenone, a selective non-steroidal mineralocorticoid receptor antagonist, is advancing the treatment of cardiorenal diseases, particularly for patients with type 2 diabetes.

The Clinical Impact of Finerenone: From Trial Data to Treatment Guidelines

Analyze the clinical evidence supporting Finerenone's use, its journey from pivotal trials to its incorporation into treatment guidelines for managing cardiorenal diseases in patients with T2DM and CKD.

Understanding Finerenone: A New Era in Cardiorenal Disease Management

Discover how Finerenone, a novel non-steroidal mineralocorticoid receptor antagonist, is revolutionizing the treatment of diabetic kidney disease and heart failure. Learn about its mechanisms, clinical benefits, and patient outcomes.